Medical Oncology

Springer Science+Business Media

Journal websitePeer review: Peer review
Evaluation status available after sign-in

About the journal

Medical Oncology is a journal published by Springer Science+Business Media in United Kingdom. It is listed in MEDLINE and PUBMED according to the sources read. Declared publication charge: 3,990 EUR. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.

Basic facts

Publisher
Springer Science+Business Media
ISSN
1357-0560 · 1559-131X
Country
United Kingdom
Access
Not open access / not declared
Declared publication charge
3,990 EUR
Declared peer-review model
peer_review

Index listings

  • MEDLINE · 1994-01-01
  • PUBMED · 2017-08-08
Indexing
MEDLINE · PUBMED
APC
3,990 EUR
Declared review time (DOAJ)
—
Actual review time (measured)
214 days received→accepted — computed from PubMed (n=94)
Activity (OpenAlex)
Active — latest works 2026
PublishLens list status
Shown after sign-in
Counts for promotion at your university?
Choose your university and rank below ↓

Methodology signals (dated facts from their sources)

Details of the evaluation under the published methodology are shown to signed-in users (free).

Create a free account to view the evaluation

Journal profile

Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.

Works in OpenAlex

5903

Last recorded publication year

2026

Reported by OpenAlex in 1 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core

h-index

110

i10-index

3390

From OpenAlex open data (CC0).

Editorial & policy6
Observed digital preservation (Keepers registry)— snapshot 2026-10-05
CLOCKSSPortico
Editorial board
Official page ↗
Norwegian register (HK-dir)— 2026
Level 1 — approved scholarly channel
Open references deposited at Crossref
91%
ORCID iDs in current deposits
27%
Enrolled in Crossref Similarity Check
✓
Deposits licence metadata at Crossref
✓
Identity & continuity3
Alternate titles
MO
Source type
journal
NLM unique ID (PubMed)
9435512
Classification(no data)

No data available to the platform for this group

No platform data for: Classification — absence is not a judgment about the journal.

Subject areas

  • Cancer-related molecular mechanisms research
  • Cancer-related molecular mechanisms research
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Treatments and Mutations
  • MicroRNA in disease regulation
  • MicroRNA in disease regulation
  • RNA modifications and cancer
  • RNA modifications and cancer
Show all subjects (50)
  • Lymphoma Diagnosis and Treatment
  • Lymphoma Diagnosis and Treatment
  • Lung Cancer Research Studies
  • Lung Cancer Research Studies
  • Cancer, Hypoxia, and Metabolism
  • Cancer-related Molecular Pathways
  • Cancer, Hypoxia, and Metabolism
  • Cancer-related Molecular Pathways
  • Cancer Immunotherapy and Biomarkers
  • Cancer Immunotherapy and Biomarkers
  • Epigenetics and DNA Methylation
  • Epigenetics and DNA Methylation
  • Chronic Lymphocytic Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Cancer Cells and Metastasis
  • Immunotherapy and Immune Responses
  • Immunotherapy and Immune Responses
  • Cancer Cells and Metastasis
  • Gastric Cancer Management and Outcomes
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Treatments and Studies
  • Cancer Genomics and Diagnostics
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Circular RNAs in diseases
  • Circular RNAs in diseases
  • Acute Myeloid Leukemia Research
  • Acute Myeloid Leukemia Research
  • Cancer, Lipids, and Metabolism
  • Cancer Treatment and Pharmacology
  • Cancer Treatment and Pharmacology
  • Pancreatic and Hepatic Oncology Research
  • HER2/EGFR in Cancer Research
  • HER2/EGFR in Cancer Research
  • Cancer, Lipids, and Metabolism
  • Pancreatic and Hepatic Oncology Research
  • Peptidase Inhibition and Analysis
  • Peptidase Inhibition and Analysis
  • Cancer Mechanisms and Therapy
  • Cancer Mechanisms and Therapy
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Hepatocellular Carcinoma Treatment and Prognosis

Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.

Loading community confirmations…
How do we evaluate?Publisher of this journal? Appeal a derived assessment or request a factual correction

The journal's record in other sources:Web of Science MJLDOAJ

Everything shown here is produced automatically from named sources (DOAJ, OpenAlex, Crossref, PubMed, the Norwegian register) as of its capture date, with no human editing. Facts appear as recorded at the source; derived scores (PCI, PTD, PublishLens score) follow a published methodology. Not a judgement on the journal, not an official accreditation, not advice.

Wrong items are corrected automatically by re-reading the source (24 h for daily sources, 7 days for weekly ones) with a dated change log, and each item links to its source record. PublishLens-derived assessments are contested through the appeals mechanism (15 working days). Appeals · Indicator guide

Norwegian register data: Kanalregisteret (HK-dir, Norway) — CC BY 4.0 / NLOD — adapted: level extracted per year · OASPA member list — CC BY

Last automated source read: